AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLOV
  4. [Form 4] Clover Health Investments, Corp Insider Trading Activity

[Form 4] Clover Health Investments, Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for Clover Health Investments Corp. (CLOV) discloses three transactions by Jamie L. Reynoso, CEO 鈥� Medicare Advantage, on July 3 and July 7, 2025.

  • Dispositions: 19,789 Class A shares sold on 7/3/25 at a weighted-average price of $2.58; 2,012 shares sold on 7/7/25 at $2.85. Both sales executed under a Rule 10b5-1 plan adopted 3/13/25.
  • Withholding for taxes: 8,706 shares automatically withheld on 7/3/25 at $2.56 to satisfy tax obligations upon RSU vesting.
  • Post-transaction ownership: Reynoso continues to hold 3,297,821 Class A shares directly.
  • The RSU award that triggered the tax withholding vests quarterly through 1/3/27, subject to continued service.

No derivative security activity was reported. The transactions represent roughly 0.66 % of Reynoso鈥檚 stated post-filing stake, indicating a modest reduction in ownership.

La dichiarazione del Modulo 4 per Clover Health Investments Corp. (CLOV) rivela tre operazioni effettuate da Jamie L. Reynoso, CEO 鈥� Medicare Advantage, il 3 e il 7 luglio 2025.

  • Disposizioni: 19.789 azioni Classe A vendute il 3/7/25 a un prezzo ponderato medio di 2,58 $; 2.012 azioni vendute il 7/7/25 a 2,85 $. Entrambe le vendite eseguite nell鈥檃mbito di un piano Rule 10b5-1 adottato il 13/3/25.
  • Ritenuta per tasse: 8.706 azioni trattenute automaticamente il 3/7/25 a 2,56 $ per soddisfare gli obblighi fiscali al momento della maturazione delle RSU.
  • Possesso post-transazione: Reynoso continua a detenere direttamente 3.297.821 azioni Classe A.
  • Il premio RSU che ha innescato la ritenuta fiscale matura trimestralmente fino al 3/1/27, subordinato al mantenimento del servizio.

Non sono state segnalate attivit脿 relative a strumenti derivati. Le operazioni rappresentano circa il 0,66% della partecipazione dichiarata da Reynoso dopo la presentazione, indicando una riduzione moderata della propriet脿.

La presentaci贸n del Formulario 4 de Clover Health Investments Corp. (CLOV) revela tres transacciones realizadas por Jamie L. Reynoso, CEO 鈥� Medicare Advantage, los 3 y 7 de julio de 2025.

  • Disposiciones: 19,789 acciones Clase A vendidas el 3/7/25 a un precio promedio ponderado de $2.58; 2,012 acciones vendidas el 7/7/25 a $2.85. Ambas ventas ejecutadas bajo un plan Rule 10b5-1 adoptado el 13/3/25.
  • Retenci贸n para impuestos: 8,706 acciones retenidas autom谩ticamente el 3/7/25 a $2.56 para cumplir con obligaciones fiscales al momento de la adquisici贸n de las RSU.
  • Propiedad posterior a la transacci贸n: Reynoso contin煤a poseyendo directamente 3,297,821 acciones Clase A.
  • La concesi贸n de RSU que activ贸 la retenci贸n fiscal se otorga trimestralmente hasta el 3/1/27, sujeto a la continuidad del servicio.

No se report贸 actividad con valores derivados. Las transacciones representan aproximadamente el 0.66% de la participaci贸n declarada por Reynoso despu茅s de la presentaci贸n, indicando una reducci贸n moderada en la propiedad.

Clover Health Investments Corp. (CLOV)鞚� Form 4 鞝滌稖靹�電� Jamie L. Reynoso, Medicare Advantage CEO臧� 2025雲� 7鞗� 3鞚缄臣 7鞗� 7鞚�鞐� 靾橅枆頃� 靹� 瓯挫潣 瓯半灅毳� 瓿店皽頃╇媹雼�.

  • 觳橂秳 雮挫棴: 2025雲� 7鞗� 3鞚检棎 臧�欷戫弶攴� 臧�瓴� $2.58搿� 19,789欤� 韥措灅鞀� A 欤检嫕 毵る弰; 7鞗� 7鞚检棎 $2.85搿� 2,012欤� 毵る弰. 霊� 毵る弰 氇憪 2025雲� 3鞗� 13鞚� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅�.
  • 靹戈笀 鞗愳矞歆曥垬: 7鞗� 3鞚检棎 RSU 氩犾姢韺� 鞁� 靹戈笀 雮╇秬毳� 鞙勴暣 8,706欤缄皜 鞛愲彊鞙茧 鞗愳矞歆曥垬霅橃棃鞙茧┌, 臧�瓴╈潃 $2.56鞛�.
  • 瓯半灅 頉� 氤挫湢 欤检嫕: Reynoso電� 歆侅爲 3,297,821欤� 韥措灅鞀� A 欤检嫕鞚� 瓿勳啀 氤挫湢 欷�.
  • 靹戈笀 鞗愳矞歆曥垬毳� 齑夒皽頃� RSU 氤挫儊鞚� 2027雲� 1鞗� 3鞚缄箤歆� 攵勱赴氤勲 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝鞚� 鞝侅毄霅�.

韺岇儩 歃濌秾 頇滊彊鞚� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞚� 瓯半灅霌れ潃 Reynoso鞚� 鞁犼碃 頉� 歆�攵勳潣 鞎� 0.66%鞐� 頃措嫻頃橃棳 靻岉彮鞚� 歆�攵� 臧愳唽毳� 雮橅儉雰呺媹雼�.

Le d茅p么t du formulaire 4 pour Clover Health Investments Corp. (CLOV) r茅v猫le trois transactions effectu茅es par Jamie L. Reynoso, PDG 鈥� Medicare Advantage, les 3 et 7 juillet 2025.

  • Dispositions : 19 789 actions de classe A vendues le 3/7/25 脿 un prix moyen pond茅r茅 de 2,58 $ ; 2 012 actions vendues le 7/7/25 脿 2,85 $. Les deux ventes ont 茅t茅 r茅alis茅es dans le cadre d鈥檜n plan Rule 10b5-1 adopt茅 le 13/3/25.
  • Retenue pour imp么ts : 8 706 actions automatiquement retenues le 3/7/25 脿 2,56 $ pour satisfaire les obligations fiscales lors de la lev茅e des RSU.
  • Possession apr猫s transaction : Reynoso d茅tient toujours directement 3 297 821 actions de classe A.
  • La r茅mun茅ration en RSU 脿 l鈥檕rigine de la retenue fiscale est acquise trimestriellement jusqu鈥檃u 3/1/27, sous r茅serve de la poursuite du service.

Aucune activit茅 sur titres d茅riv茅s n鈥檃 茅t茅 signal茅e. Les transactions repr茅sentent environ 0,66 % de la participation d茅clar茅e par Reynoso apr猫s d茅p么t, indiquant une l茅g猫re r茅duction de sa d茅tention.

Die Form 4-Meldung f眉r Clover Health Investments Corp. (CLOV) offenbart drei Transaktionen von Jamie L. Reynoso, CEO 鈥� Medicare Advantage, am 3. und 7. Juli 2025.

  • 痴别谤盲耻脽别谤耻苍驳别苍: Am 3.7.25 wurden 19.789 Class A-Aktien zu einem gewichteten Durchschnittspreis von 2,58 $ verkauft; am 7.7.25 wurden 2.012 Aktien zu 2,85 $ verkauft. Beide Verk盲ufe erfolgten im Rahmen eines Rule 10b5-1-Plans, der am 13.3.25 angenommen wurde.
  • Steuerabzug: Am 3.7.25 wurden automatisch 8.706 Aktien zu 2,56 $ einbehalten, um Steuerpflichten bei der RSU-Vesting zu erf眉llen.
  • Besitz nach der Transaktion: Reynoso h盲lt weiterhin direkt 3.297.821 Class A-Aktien.
  • Die RSU-Zuteilung, die den Steuerabzug ausgel枚st hat, vestet viertelj盲hrlich bis zum 3.1.27, vorbehaltlich fortgesetzter Dienstzeit.

Es wurden keine Aktivit盲ten mit Derivaten gemeldet. Die Transaktionen entsprechen etwa 0,66 % von Reynos angegebenem Anteil nach der Meldung und stellen eine moderate Reduzierung des Eigentums dar.

Positive
  • High residual ownership: Jamie L. Reynoso still holds 3.3 million Class A shares, maintaining strong equity alignment.
Negative
  • Insider selling activity: Disposition of 21,801 shares may be perceived negatively, though size is immaterial (<1% of holding).

Insights

TL;DR: Small insider sale (<1% stake) under 10b5-1 plan; minimal impact on valuation.

The combined 21,801-share sale, worth roughly $56k, is immaterial relative to Clover鈥檚 market capitalization and to Reynoso鈥檚 3.3 million-share holding. Execution under a pre-planned 10b5-1 agreement limits signaling value. Tax-related share withholding is standard. Overall, the filing offers few clues about near-term fundamentals.

TL;DR: Governance-neutral event; adequate disclosure, large residual stake aligns incentives.

Use of a Rule 10b5-1 plan and detailed footnotes comply with SEC best practices, reducing concerns over opportunistic trading. Reynoso鈥檚 remaining 3.3 million shares preserve alignment with shareholders. No red flags emerge, but persistent small disposals could merit trend monitoring.

La dichiarazione del Modulo 4 per Clover Health Investments Corp. (CLOV) rivela tre operazioni effettuate da Jamie L. Reynoso, CEO 鈥� Medicare Advantage, il 3 e il 7 luglio 2025.

  • Disposizioni: 19.789 azioni Classe A vendute il 3/7/25 a un prezzo ponderato medio di 2,58 $; 2.012 azioni vendute il 7/7/25 a 2,85 $. Entrambe le vendite eseguite nell鈥檃mbito di un piano Rule 10b5-1 adottato il 13/3/25.
  • Ritenuta per tasse: 8.706 azioni trattenute automaticamente il 3/7/25 a 2,56 $ per soddisfare gli obblighi fiscali al momento della maturazione delle RSU.
  • Possesso post-transazione: Reynoso continua a detenere direttamente 3.297.821 azioni Classe A.
  • Il premio RSU che ha innescato la ritenuta fiscale matura trimestralmente fino al 3/1/27, subordinato al mantenimento del servizio.

Non sono state segnalate attivit脿 relative a strumenti derivati. Le operazioni rappresentano circa il 0,66% della partecipazione dichiarata da Reynoso dopo la presentazione, indicando una riduzione moderata della propriet脿.

La presentaci贸n del Formulario 4 de Clover Health Investments Corp. (CLOV) revela tres transacciones realizadas por Jamie L. Reynoso, CEO 鈥� Medicare Advantage, los 3 y 7 de julio de 2025.

  • Disposiciones: 19,789 acciones Clase A vendidas el 3/7/25 a un precio promedio ponderado de $2.58; 2,012 acciones vendidas el 7/7/25 a $2.85. Ambas ventas ejecutadas bajo un plan Rule 10b5-1 adoptado el 13/3/25.
  • Retenci贸n para impuestos: 8,706 acciones retenidas autom谩ticamente el 3/7/25 a $2.56 para cumplir con obligaciones fiscales al momento de la adquisici贸n de las RSU.
  • Propiedad posterior a la transacci贸n: Reynoso contin煤a poseyendo directamente 3,297,821 acciones Clase A.
  • La concesi贸n de RSU que activ贸 la retenci贸n fiscal se otorga trimestralmente hasta el 3/1/27, sujeto a la continuidad del servicio.

No se report贸 actividad con valores derivados. Las transacciones representan aproximadamente el 0.66% de la participaci贸n declarada por Reynoso despu茅s de la presentaci贸n, indicando una reducci贸n moderada en la propiedad.

Clover Health Investments Corp. (CLOV)鞚� Form 4 鞝滌稖靹�電� Jamie L. Reynoso, Medicare Advantage CEO臧� 2025雲� 7鞗� 3鞚缄臣 7鞗� 7鞚�鞐� 靾橅枆頃� 靹� 瓯挫潣 瓯半灅毳� 瓿店皽頃╇媹雼�.

  • 觳橂秳 雮挫棴: 2025雲� 7鞗� 3鞚检棎 臧�欷戫弶攴� 臧�瓴� $2.58搿� 19,789欤� 韥措灅鞀� A 欤检嫕 毵る弰; 7鞗� 7鞚检棎 $2.85搿� 2,012欤� 毵る弰. 霊� 毵る弰 氇憪 2025雲� 3鞗� 13鞚� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅�.
  • 靹戈笀 鞗愳矞歆曥垬: 7鞗� 3鞚检棎 RSU 氩犾姢韺� 鞁� 靹戈笀 雮╇秬毳� 鞙勴暣 8,706欤缄皜 鞛愲彊鞙茧 鞗愳矞歆曥垬霅橃棃鞙茧┌, 臧�瓴╈潃 $2.56鞛�.
  • 瓯半灅 頉� 氤挫湢 欤检嫕: Reynoso電� 歆侅爲 3,297,821欤� 韥措灅鞀� A 欤检嫕鞚� 瓿勳啀 氤挫湢 欷�.
  • 靹戈笀 鞗愳矞歆曥垬毳� 齑夒皽頃� RSU 氤挫儊鞚� 2027雲� 1鞗� 3鞚缄箤歆� 攵勱赴氤勲 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝鞚� 鞝侅毄霅�.

韺岇儩 歃濌秾 頇滊彊鞚� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞚� 瓯半灅霌れ潃 Reynoso鞚� 鞁犼碃 頉� 歆�攵勳潣 鞎� 0.66%鞐� 頃措嫻頃橃棳 靻岉彮鞚� 歆�攵� 臧愳唽毳� 雮橅儉雰呺媹雼�.

Le d茅p么t du formulaire 4 pour Clover Health Investments Corp. (CLOV) r茅v猫le trois transactions effectu茅es par Jamie L. Reynoso, PDG 鈥� Medicare Advantage, les 3 et 7 juillet 2025.

  • Dispositions : 19 789 actions de classe A vendues le 3/7/25 脿 un prix moyen pond茅r茅 de 2,58 $ ; 2 012 actions vendues le 7/7/25 脿 2,85 $. Les deux ventes ont 茅t茅 r茅alis茅es dans le cadre d鈥檜n plan Rule 10b5-1 adopt茅 le 13/3/25.
  • Retenue pour imp么ts : 8 706 actions automatiquement retenues le 3/7/25 脿 2,56 $ pour satisfaire les obligations fiscales lors de la lev茅e des RSU.
  • Possession apr猫s transaction : Reynoso d茅tient toujours directement 3 297 821 actions de classe A.
  • La r茅mun茅ration en RSU 脿 l鈥檕rigine de la retenue fiscale est acquise trimestriellement jusqu鈥檃u 3/1/27, sous r茅serve de la poursuite du service.

Aucune activit茅 sur titres d茅riv茅s n鈥檃 茅t茅 signal茅e. Les transactions repr茅sentent environ 0,66 % de la participation d茅clar茅e par Reynoso apr猫s d茅p么t, indiquant une l茅g猫re r茅duction de sa d茅tention.

Die Form 4-Meldung f眉r Clover Health Investments Corp. (CLOV) offenbart drei Transaktionen von Jamie L. Reynoso, CEO 鈥� Medicare Advantage, am 3. und 7. Juli 2025.

  • 痴别谤盲耻脽别谤耻苍驳别苍: Am 3.7.25 wurden 19.789 Class A-Aktien zu einem gewichteten Durchschnittspreis von 2,58 $ verkauft; am 7.7.25 wurden 2.012 Aktien zu 2,85 $ verkauft. Beide Verk盲ufe erfolgten im Rahmen eines Rule 10b5-1-Plans, der am 13.3.25 angenommen wurde.
  • Steuerabzug: Am 3.7.25 wurden automatisch 8.706 Aktien zu 2,56 $ einbehalten, um Steuerpflichten bei der RSU-Vesting zu erf眉llen.
  • Besitz nach der Transaktion: Reynoso h盲lt weiterhin direkt 3.297.821 Class A-Aktien.
  • Die RSU-Zuteilung, die den Steuerabzug ausgel枚st hat, vestet viertelj盲hrlich bis zum 3.1.27, vorbehaltlich fortgesetzter Dienstzeit.

Es wurden keine Aktivit盲ten mit Derivaten gemeldet. Die Transaktionen entsprechen etwa 0,66 % von Reynos angegebenem Anteil nach der Meldung und stellen eine moderate Reduzierung des Eigentums dar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynoso Jamie L.
(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE
(Street)
WILMINGTON DE 19801
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Medicare Advantage
3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/03/2025 S 19,789(1) D $2.58 3,308,539 D
Class A Common Stock 07/03/2025 F 8,706(2) D $2.56 3,299,833 D
Class A Common Stock 07/07/2025 S 2,012(3) D $2.85 3,297,821 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.63, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations due to the vesting on July 3, 2025, of 6.25% of the restricted stock units ("RSUs") granted to the Reporting Person on January 3, 2023, and originally reported on a Form 4 filed on January 5, 2023. The remaining RSUs will vest in equal quarterly installments, with the final vesting occurring on January 3, 2027, in each case subject to the continued service of the Reporting Person on each such vesting date.
3. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.81 to $2.88, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso 07/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Clover Health (CLOV) shares did Jamie L. Reynoso sell?

21,801 shares were sold (19,789 on 7/3/25 and 2,012 on 7/7/25).

At what prices were the CLOV shares sold?

Weighted-average prices were $2.58 on 7/3/25 and $2.85 on 7/7/25.

Why were 8,706 CLOV shares disposed of without a sale?

They were withheld to cover taxes on the vesting of RSUs granted 1/3/23.

Does the Form 4 indicate ongoing RSU vesting for Reynoso?

Yes. The remaining RSUs vest quarterly until January 3, 2027, contingent on continued service.

What is Jamie L. Reynoso鈥檚 remaining CLOV share ownership?

After the transactions, she directly owns 3,297,821 Class A shares.

Were the sales under a Rule 10b5-1 trading plan?

Yes. Both sales were executed pursuant to a 10b5-1 plan adopted on March 13, 2025.
Stock CLOV logo
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

#2840 Ranked by Market Cap
N/A Ranked by Dividends

CLOV Latest News

Jul 9, 2025
Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC鈥檚 iCare+ Network
Jul 8, 2025
Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025
Jun 30, 2025
Clover Health Set to Join Russell 3000庐 Index
May 6, 2025
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
May 1, 2025
Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

CLOV Latest SEC Filings

Jul 8, 2025
[144] Clover Health Investments, Corp SEC Filing
Jul 7, 2025
[144] Clover Health Investments, Corp SEC Filing
Jul 3, 2025
[Form 4] Clover Health Investments, Corp Insider Trading Activity
Jul 3, 2025
[144] Clover Health Investments, Corp SEC Filing
Jul 2, 2025
[Form 4] Clover Health Investments, Corp Insider Trading Activity

CLOV Stock Data

1.40B
400.24M
5.09%
22.38%
2.33%
Healthcare Plans
Hospital & Medical Service Plans
United States
JERSEY CITY